Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells

Häggblad Sahlberg,Sara; Mortensen,Anja C.; Haglöf,Jakob; Engskog,Mikael K.R.; Arvidsson,Torbjörn; Pettersson,Curt; Glimelius,Bengt; Stenerlöw,Bo; Nestor,Marika

doi:10.3892/ijo.2016.3771

Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells

Authors:
- Sara Häggblad Sahlberg
- Anja C. Mortensen
- Jakob Haglöf
- Mikael K.R. Engskog
- Torbjörn Arvidsson
- Curt Pettersson
- Bengt Glimelius
- Bo Stenerlöw
- Marika Nestor
View Affiliations

Affiliations: Department of Immunology, Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden, Division of Analytical Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, SE-751 23 Uppsala, Sweden
Published online on: November 18, 2016 https://doi.org/10.3892/ijo.2016.3771
Pages: 5-14
Copyright: © Häggblad Sahlberg et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

AKT is a central protein in many cellular pathways such as cell survival, proliferation, glucose uptake, metabolism, angiogenesis, as well as radiation and drug response. The three isoforms of AKT (AKT1, AKT2 and AKT3) are proposed to have different physiological functions, properties and expression patterns in a cell type-dependent manner. As of yet, not much is known about the influence of the different AKT isoforms in the genome and their effects in the metabolism of colorectal cancer cells. In the present study, DLD-1 isogenic AKT1, AKT2 and AKT1/2 knockout colon cancer cell lines were used as a model system in conjunction with the parental cell line in order to further elucidate the differences between the AKT isoforms and how they are involved in various cellular pathways. This was done using genome wide expression analyses, metabolic profiling and cell migration assays. In conclusion, downregulation of genes in the cell adhesion, extracellular matrix and Notch-pathways and upregulation of apoptosis and metastasis inhibitory genes in the p53-pathway, confirm that the knockout of both AKT1 and AKT2 will attenuate metastasis and tumor cell growth. This was verified with a reduction in migration rate in the AKT1 KO and AKT2 KO and most explicitly in the AKT1/2 KO. Furthermore, the knockout of AKT1, AKT2 or both, resulted in a reduction in lactate and alanine, suggesting that the metabolism of carbohydrates and glutathione was impaired. This was further verified in gene expression analyses, showing downregulation of genes involved in glucose metabolism. Additionally, both AKT1 KO and AKT2 KO demonstrated an impaired fatty acid metabolism. However, genes were upregulated in the Wnt and cell proliferation pathways, which could oppose this effect. AKT inhibition should therefore be combined with other effectors to attain the best effect.

View Figures

View References

1	Pal SK, Reckamp K, Yu H and Figlin RA: Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 19:1355–1366. 2010. View Article : Google Scholar : PubMed/NCBI
2	Cheung M and Testa JR: Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets. 13:234–244. 2013. View Article : Google Scholar : PubMed/NCBI
3	Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J and Rosen N: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 19:58–71. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hollander MC, Maier CR, Hobbs EA, Ashmore AR, Linnoila RI and Dennis PA: Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene. 30:1812–1821. 2011. View Article : Google Scholar : PubMed/NCBI
5	Romano G: The role of the dysfunctional akt-related pathway in cancer: Establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development. Scientifica (Cairo). 2013:3171862013.
6	Virtakoivu R, Pellinen T, Rantala JK, Perälä M and Ivaska J: Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell. 23:3357–3369. 2012. View Article : Google Scholar : PubMed/NCBI
7	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
8	Gonzalez E and McGraw TE: The Akt kinases: Isoform specificity in metabolism and cancer. Cell Cycle. 8:2502–2508. 2009. View Article : Google Scholar : PubMed/NCBI
9	Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, et al: Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest. 112:197–208. 2003. View Article : Google Scholar : PubMed/NCBI
10	Katome T, Obata T, Matsushima R, Masuyama N, Cantley LC, Gotoh Y, Kishi K, Shiota H and Ebina Y: Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J Biol Chem. 278:28312–28323. 2003. View Article : Google Scholar : PubMed/NCBI
11	Simons A, Orcutt K, Madsen J, Scarbrough P and Spitz D: The role of Akt pathway signaling in glucose metabolism and metabolic oxidative stress. Oxidative Stress in Cancer Biology and Therapy. Spitz DR, Dornfeld KJ, Krishnan K and Gius D: Humana Press; New York: pp. 21–46. 2012, View Article : Google Scholar
12	Sahlberg SH, Gustafsson AS, Pendekanti PN, Glimelius B and Stenerlow B: The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines. Tumour Biol. 35:3525–3534. 2014. View Article : Google Scholar :
13	Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B and Nestor M: Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radioresistance in colon cancer cells. PLoS One. e946212014. View Article : Google Scholar
14	Li C and Wong WH: Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci USA. 98:31–36. 2001. View Article : Google Scholar : PubMed/NCBI
15	Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:Article3. 2004.
16	Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B. 57:289–300. 1995.
17	Liang CC, Park AY and Guan JL: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
18	Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TW, Fiehn O, Goodacre R, Griffin JL, et al: Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics. 3:211–221. 2007. View Article : Google Scholar : PubMed/NCBI
19	Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, et al: HMDB 3.0 - The Human Metabolome Database in 2013. Nucleic Acids Res. 41(D1): D801–D807. 2013. View Article : Google Scholar
20	Trygg J and Wold S: Orthogonal projections to latent structures (O-PLS). J Chemometr. 16:119–128. 2002. View Article : Google Scholar
21	Makrilia N, Kollias A, Manolopoulos L and Syrigos K: Cell adhesion molecules: Role and clinical significance in cancer. Cancer Invest. 27:1023–1037. 2009. View Article : Google Scholar : PubMed/NCBI
22	Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B and Papadopoulos N: Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci USA. 107:2598–2603. 2010. View Article : Google Scholar : PubMed/NCBI
23	Takebe N, Nguyen D and Yang SX: Targeting notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar :
24	Phillips TM, McBride WH and Pajonk F: The response of CD24⁻/low/CD44⁺ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 98:1777–1785. 2006. View Article : Google Scholar : PubMed/NCBI
25	Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, Harris AL and Muschel RJ: Delta-like ligand 4-notch blockade and tumor radiation response. J Natl Cancer Inst. 103:1778–1798. 2011. View Article : Google Scholar : PubMed/NCBI
26	de Sousa EM, Vermeulen L, Richel D and Medema JP: Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res. 17:647–653. 2011. View Article : Google Scholar
27	Yang J, Zhang W, Evans PM, Chen X, He X and Liu C: Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem. 281:17751–17757. 2006. View Article : Google Scholar : PubMed/NCBI
28	Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B and Papadopoulos N: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA. 106:3964–3969. 2009. View Article : Google Scholar : PubMed/NCBI
29	DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S and Thompson CB: Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 104:19345–19350. 2007. View Article : Google Scholar : PubMed/NCBI
30	Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
31	Currie E, Schulze A, Zechner R, Walther TC and Farese RV Jr: Cellular fatty acid metabolism and cancer. Cell Metab. 18:153–161. 2013. View Article : Google Scholar : PubMed/NCBI
32	Oermann EK, Wu J, Guan KL and Xiong Y: Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol. 23:370–380. 2012. View Article : Google Scholar : PubMed/NCBI
33	Johansson K, Ahlen K, Rinaldi R, Sahlander K, Siritantikorn A and Morgenstern R: Microsomal glutathione transferase 1 in anticancer drug resistance. Carcinogenesis. 28:465–470. 2007. View Article : Google Scholar
34	Cho SG, Lee YH, Park HS, Ryoo K, Kang KW, Park J, Eom SJ, Kim MJ, Chang TS, Choi SY, et al: Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J Biol Chem. 276:12749–12755. 2001. View Article : Google Scholar : PubMed/NCBI
35	Choi SW and Mason JB: Folate and carcinogenesis: An integrated scheme. J Nutr. 130:129–132. 2000.PubMed/NCBI
36	Harmenberg U, Frodin JE, Ljungdahl-Stahle E, Mellstedt H, Wahren B and Stigbrand T: Significance of alkaline phosphatase isozymes in the monitoring of patients with colorectal carcinoma. Tumour Biol. 10:225–231. 1989. View Article : Google Scholar : PubMed/NCBI
37	Cho YR, Kim SH, Ko HY, Kim MD, Choi SW and Seo DW: Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70S6K-dependent VEGFR-2 expression. Oncol Rep. 26:861–867. 2011.PubMed/NCBI
38	Lamarre SG, Morrow G, Macmillan L, Brosnan ME and Brosnan JT: Formate: an essential metabolite, a biomarker, or more? Clin Chem Lab Med. 51:571–578. 2013. View Article : Google Scholar